Jennison Associates
BMY icon

Jennison Associates’s Bristol-Myers Squibb BMY Stock Holding History

Jennison Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200,000
Closed -$12.7M – 660
2018
Q1 		$12.7M Buy
200,000
+25,000
+14% +$1.61M 0.01% 440
2017
Q4 		$10.7M Buy
+175,000
New +$10.9M 0.01% 456

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jennison Associates's BMY Position: Q4 2025 in Review

Jennison Associates sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 21,733 shares — an estimated $980K sold.

Jennison Associates first reported a position in BMY in Q2 2013 and held it in 50 quarters. The position peaked at $2.06B in Q2 2016. 2,456 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Jennison Associates reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Jennison Associates sold 21,733 Bristol-Myers Squibb shares in Q4 2025, an estimated $980K.
  • Jennison Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 50 quarters.
  • Jennison Associates's Bristol-Myers Squibb position peaked at $2.06B in Q2 2016.
  • 2,456 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.